

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings in this application.

**Listing of Claims**

1. (Original) A pharmaceutical composition for treating and preventing a disease and a disorder associated with an ischemic condition of a brain, and a disease and a disorder caused by the disease and the disorder, the composition comprising:  
  
at least one NF- $\kappa$ B decoy; and  
  
a pharmaceutically acceptable carrier.
2. (Original) A composition according to claim 1, wherein the disease is at least one disease selected from the group consisting of subarachnoid hemorrhage, hypertensive intracerebral hemorrhage, cerebral infarct, brain ischemia, brain tumor, head injury, chronic subdural hemorrhage, and acute subdural hemorrhage.
3. (Original) A composition according to claim 1, wherein the disease and the disorder caused by the disease and the disorder associated with the ischemic condition of the brain is selected from the group consisting of neuropathy, motor disorders, intelligence disorder, dementia, partial paralysis, headache, and incontinence of urine.
4. (Original) A composition according to claim 1, wherein the pharmaceutically acceptable carrier is a liposome.
5. (Original) A composition according to claim 1, wherein the NF- $\kappa$ B decoy comprises a sequence GGATTTCCTCC.

6. (Original) A composition according to claim 1, wherein the composition is appropriate to an administration route including a carotid artery.

7. (Original) A composition for carrying out gene transfection in a brain by a route other than direct administration to the brain, the composition comprising:

at least one decoy; and

a pharmaceutically acceptable carrier.

8. (Original) A composition according to claim 7, wherein the route other than direct administration to the brain is an infusion to a carotid artery.

9. (Original) A composition according to claim 7, wherein the decoy is NF- $\kappa$ B.

10. (Original) A composition according to claim 7, wherein the pharmaceutically acceptable carrier is a liposome.

11. (Original) A method for treating and preventing a disease and a disorder associated with an ischemic condition of a brain, and a disease and a disorder caused by the disease and the disorder, the method comprising the step of:

administering a composition to a subject,

wherein the composition comprises:

at least one NF- $\kappa$ B decoy; and

a pharmaceutically acceptable carrier.

12. (Original) A method according to claim 11, wherein the disease is at least one disease selected from the group consisting of subarachnoid hemorrhage, hypertensive intracerebral hemorrhage, cerebral infarct, brain ischemia, brain tumor, head injury, chronic subdural hemorrhage, and acute subdural hemorrhage.

13. (Original) A method according to claim 11, wherein the disease and the disorder caused by the disease and the disorder associated with the ischemic condition of the brain is selected from the group consisting of neuropathy, motor disorders, intelligence disorder, dementia, partial paralysis, headache, and incontinence of urine.

14. (Original) A method according to claim 11, wherein the pharmaceutically acceptable carrier is a liposome.

15. (Original) A method according to claim 11, wherein the NF- $\kappa$ B decoy comprises a sequence GGATTTCCC.

16. (Original) A method according to claim 11, wherein the composition is appropriate to an administration route including a carotid artery.

17. (Original) A method for carrying out gene transfection in a brain by a route other than direct administration to the brain, the method comprising the step of:

administering a composition into the route other than the direct administration to the brain,

wherein the composition comprises, in an appropriate form:

at least one decoy; and

a pharmaceutically acceptable carrier.

18. (Original) A method according to claim 17, wherein the route other than direct administration to the brain is an infusion to a carotid artery.

19. (Original) A method according to claim 17, wherein the decoy is NF- $\kappa$ B.

20. (Original) A method according to claim 17, wherein the pharmaceutically acceptable carrier is a liposome.